Clinical Development Contract Manufacturing Development Licensing 
Roots Analysis
FEBRUARY 27, 2024
On November 1, 2019, Avacta Group and ADC Therapeutics have announced a collaboration agreement for the development of novel drug candidates. The firm also has the right to obtain exclusive licenses to the Affimer proteins for clinical development and commercialization.
The Pharma Data
JUNE 2, 2022
Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Roots Analysis
FEBRUARY 26, 2024
In fact, the share of biologics in the overall pharmaceutical contract manufacturing market has increased from 16% in 2006 to over 25% in 2017. Biologics constitute a majority of the top selling drugs and represent one of the fastest growing segments of the overall pharmaceutical industry.
The Pharma Data
MARCH 16, 2021
Aligning with a circuitry-based approach to precision psychiatry, the collaboration will leverage Boehringer Ingelheim’s deep experience in central nervous system (CNS) drug discovery and development alongside Lieber’s expertise in centrally acting COMT inhibitors. The Lieber Institute for Brain Development. Weinberger, M.D.,
pharmaphorum
JANUARY 7, 2021
It gave CureVac €75 million in funding to develop CVnCoV last July, adding to around €100 million provided by the German government in 2020. At last count, there are more than 60 coronavirus vaccines at in clinical development around the world, with another 170 in preclinical testing, according to the World Health Organization (WHO).
The Pharma Data
MARCH 2, 2021
Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity. After initial maturation, projects are handed over for further development to Boehringer Ingelheim. About Boehringer Ingelheim.
The Pharma Data
JULY 21, 2021
Biovac will perform manufacturing and distribution activities within Pfizer’s and BioNTech’s global COVID-19 vaccine supply chain and manufacturing network, which will now span three continents and include more than 20 manufacturing facilities. The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S.
Expert insights. Personalized for you.
52 
Let's personalize your content